These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 29545347)

  • 21. Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.
    Blood; 2018 Mar; 131(13):1495. PubMed ID: 29599148
    [No Abstract]   [Full Text] [Related]  

  • 22. Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma.
    Desantis V; Frassanito MA; Tamma R; Saltarella I; Di Marzo L; Lamanuzzi A; Solimando AG; Ruggieri S; Annese T; Nico B; Vacca A; Ribatti D
    Ann Hematol; 2018 Jul; 97(7):1251-1258. PubMed ID: 29589107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma.
    Hildebrandt GC; Berno T; Gurule A; Mohan M; Yoon D; Salama M; Zangari M
    Br J Haematol; 2019 Jan; 184(2):308-310. PubMed ID: 29574687
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.
    Davies FE; Rosenthal A; Rasche L; Petty NM; McDonald JE; Ntambi JA; Steward DM; Panozzo SB; van Rhee F; Zangari M; Schinke CD; Thanendrarajan S; Walker B; Weinhold N; Barlogie B; Hoering A; Morgan GJ
    Haematologica; 2018 Jun; 103(6):1047-1053. PubMed ID: 29567784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study.
    Thorsteinsdottir S; Dickman PW; Landgren O; Blimark C; Hultcrantz M; Turesson I; Björkholm M; Kristinsson SY
    Haematologica; 2018 Sep; 103(9):e412-e415. PubMed ID: 29567776
    [No Abstract]   [Full Text] [Related]  

  • 26. The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma.
    Kawamura K; Tsukada N; Kanda Y; Ikeda T; Yoshida A; Ueda Y; Ishida T; Suzuki K; Murakami H
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1392-1398. PubMed ID: 29555314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe abdominal pain and diarrhea - unusual multiple myeloma presentation with a severe prognosis: a case report.
    Salguero DA; Barletta PA; Sierraalta W
    J Med Case Rep; 2018 Mar; 12(1):70. PubMed ID: 29549883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis.
    Puig N; Paiva B; Lasa M; Burgos L; Perez JJ; Merino J; Moreno C; Vidriales MB; Toboso DG; Cedena MT; Ocio EM; Lecumberri R; García de Coca A; Labrador J; Gonzalez ME; Palomera L; Gironella M; Cabañas V; Casanova M; Oriol A; Krsnik I; Pérez-Montaña A; de la Rubia J; de la Puerta JE; de Arriba F; Prosper F; Martinez-Lopez J; Lecrevisse Q; Verde J; Mateos MV; Lahuerta JJ; Orfao A; San Miguel JF
    Leukemia; 2019 May; 33(5):1256-1267. PubMed ID: 30542145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma.
    Herrero AB; Quwaider D; Corchete LA; Mateos MV; García-Sanz R; Gutiérrez NC
    J Cell Mol Med; 2020 Apr; 24(7):4171-4182. PubMed ID: 32141701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background.
    Rojas EA; Corchete LA; Mateos MV; García-Sanz R; Misiewicz-Krzeminska I; Gutiérrez NC
    Blood Cancer J; 2019 Nov; 9(12):90. PubMed ID: 31748515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anadenanthera colubrina regulated LPS-induced inflammation by suppressing NF-κB and p38-MAPK signaling pathways.
    Maia CMA; Vasconcelos PGS; Pasetto S; Godwin WC; Silva JPRE; Tavares JF; Pardi V; Costa EMMB; Murata RM
    Sci Rep; 2024 Jul; 14(1):16028. PubMed ID: 38992070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.
    Cardona-Benavides IJ; Misiewicz-Krzeminska I; Rojas EA; De Ramón C; Sanz-Solas A; Isidro I; Quwaider D; López-Guerrero AM; Cuadrado M; Calasanz MJ; Rosiñol L; Martínez-López J; San Miguel JF; Mateos MV; Corchete LA; Gutiérrez NC
    Haematologica; 2024 Mar; 109(3):877-887. PubMed ID: 37646661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.
    Rojas EA; Corchete LA; De Ramón C; Krzeminski P; Quwaider D; García-Sanz R; Martínez-López J; Oriol A; Rosiñol L; Bladé J; Lahuerta JJ; San Miguel JF; González M; Mateos MV; Bourdon JC; Misiewicz-Krzeminska I; Gutiérrez NC
    Am J Hematol; 2022 Jun; 97(6):700-710. PubMed ID: 35188691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma.
    Misiewicz-Krzeminska I; de Ramón C; Corchete LA; Krzeminski P; Rojas EA; Isidro I; García-Sanz R; Martínez-López J; Oriol A; Bladé J; Lahuerta JJ; San Miguel J; Rosiñol L; Mateos MV; Gutiérrez NC
    Blood Adv; 2020 Dec; 4(23):6023-6033. PubMed ID: 33284947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Incorporation of Extracellular Vesicles from Mesenchymal Stromal Cells Into CD34
    Preciado S; Muntión S; Corchete LA; Ramos TL; de la Torre AG; Osugui L; Rico A; Espinosa-Lara N; Gastaca I; Díez-Campelo M; Del Cañizo C; Sánchez-Guijo F
    Stem Cells; 2019 Oct; 37(10):1357-1368. PubMed ID: 31184411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies.
    Harding T; Baughn L; Kumar S; Van Ness B
    Leukemia; 2019 Apr; 33(4):863-883. PubMed ID: 30683909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.
    Misiewicz-Krzeminska I; Corchete LA; Rojas EA; Martínez-López J; García-Sanz R; Oriol A; Bladé J; Lahuerta JJ; Miguel JS; Mateos MV; Gutiérrez NC
    Haematologica; 2018 May; 103(5):880-889. PubMed ID: 29545347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capillary Nano-immunoassay for Quantification of Proteins from CD138-purified Myeloma Cells.
    Misiewicz-Krzeminska I; Isidro I; Gutiérrez NC
    Bio Protoc; 2019 Jun; 9(12):e3267. PubMed ID: 33654787
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.